熱門資訊> 正文
USANA Health预计2025财年净销售额将超过预期
2026-01-12 19:52
- USANA Health Sciences (USNA) currently anticipates fiscal year 2025 consolidated net sales of around $925M, ahead of its most recently issued guidance of ~$920M and consensus estimate of $919.85M.
- Net sales from USANA, the firm’s core nutritional business, are estimated to be around $777M; Hiya sales are expected to be ~$132M; and Rise Wellness sales are expected to be ~$16M.
- The company is issuing its initial net sales outlook for fiscal year 2026 in the range of $925M to $1B. This includes $720M to $765M from USANA, $140M to $155M from Hiya, and $65M to $80M from Rise Wellness.
- USNA +1.4% premarket to $20.14
- Source: Press Release
More on USANA Health Sciences
- USANA Health Sciences, Inc. 2025 Q3 - Results - Earnings Call Presentation
- USANA Health Sciences, Inc. (USNA) Q3 2025 Earnings Call Transcript
- Usana signals in-house Hiya manufacturing and cost reduction initiatives while expanding DTC strategy
- USANA Health Sciences Non-GAAP EPS of -$0.15 in-line, revenue of $213.67M in-line
- Seeking Alpha’s Quant Rating on USANA Health Sciences
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
